
<DOC>
<DOCNO>WT01-B21-49</DOCNO>
<DOCOLDNO>IA087-000627-B018-258</DOCOLDNO>
<DOCHDR>
http://206.61.184.43:80/schaffer/hemp/medical/hunting1.htm 206.61.184.43 19970122052659 text/html 3663
HTTP/1.0 200 OK
Date: Wednesday, 22-Jan-97 05:26:53 GMT
Server: WebSitePro/1.1f (S/N wpo-0deb)
Allow-ranges: bytes
Content-type: text/html
Last-modified: Saturday, 28-Dec-96 06:04:37 GMT
Content-length: 3446
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Effects of Cannabidiol in Huntington's Disease</title>
<meta name="FORMATTER" content="Microsoft FrontPage 2.0">
</head>

<body stylesrc="../../../_private/schaffer_style.htm"
background="../../../images/whttxtr2.jpg" bgcolor="#F2F2F2">
<!--webbot bot="Include"
u-include="../../../_private/schaffer_logo.htm" tag="BODY"
startspan -->

<p align="center"><img src="../../../images/schlogo_small.gif"
align="bottom" width="583" height="38"> </p>
<!--webbot bot="Include" endspan i-checksum="1994" --><!--webbot
bot="Include"
u-include="../../../_private/sch_hemp_medical_navbar.htm"
tag="BODY" startspan -->

<p><a href="../../../toc.htm">Contents</a> | <a
href="../../../feedback.htm">Feedback</a> | <a
href="../../../search.htm">Search</a> </p>

<p><a href="../../../index.htm">DRCNet Library</a> | <a
href="../../index.HTM">Schaffer Library</a>&nbsp;| <a
href="../hempmenu.htm">Hemp (Marijuana)</a> | <a
href="medical.htm">Medical Information</a> </p>
<!--webbot bot="Include" endspan i-checksum="55454" -->

<hr>

<p><font size="5">&nbsp;EFFECTS OF CANNABIDIOL IN HUNTINGTON'S
DISEASE&nbsp;</font></p>

<p><font size="3">Neurology 36 (Suppl 1) April 1986 p. 342 &nbsp;</font></p>

<p><font size="3">Reuven Sandyk, Paul Consroe, Lawrence Z. Stern,
and Stuart R. Snider, Tucson, AZ</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">Cannabidiol (CBD) is a major nonpsychoactive
cannabinoid of marijuana. Based on reports indicating possible
efficacy of CBD in dystonic movements (Neurology 1984; 34 [Suppl
1]: 147 and 1985; 35 [Suppl 1]: 201), we tried CBD in three
patients with Huntington's disease (HD). The patients;, aged 30
to 56, had HD of 7 to 12 years' duration. Their condition has
been slowly progressive and unresponsive to prior therapy with
neuroleptics. Orally administered CBD was initiated at 300 mg/d
and increased 1 week later to 600 mg/d for the next 3 weeks. Mild
improvement ( 5 to 15%) in the choreic movements was documented
using the tongueprotrusion test (Neurology [Minneap} 1972; 22:
929-33) and a chorea severity evaluation scale (Br J Clin
Pharmacol 1981; 11: 129-51) after the first week. Further
improvement (20 to 40%) was noticed after the second week of CBD,
and this remained stable for the following 2 weeks. </font></p>

<p><font size="3">Except for transient, mild hypotension, no side
effects were recorded, and laboratory tests were normal.
Withdrawal of CBD after 48 hours resulted in return of choreic
movements to the pre-CBD state. &nbsp;</font></p>

<p><font size="3">(Supported in part by NINCDS grant #NS15441) </font></p>

<p><font size="3"></font>&nbsp;</p>

<hr>
<!--webbot bot="Include"
u-include="../../../_private/sch_hemp_medical_navbar.htm"
tag="BODY" startspan -->

<p><a href="../../../toc.htm">Contents</a> | <a
href="../../../feedback.htm">Feedback</a> | <a
href="../../../search.htm">Search</a> </p>

<p><a href="../../../index.htm">DRCNet Library</a> | <a
href="../../index.HTM">Schaffer Library</a>&nbsp;| <a
href="../hempmenu.htm">Hemp (Marijuana)</a> | <a
href="medical.htm">Medical Information</a> </p>
<!--webbot bot="Include" endspan i-checksum="55454" -->
</body>
</html>
</DOC>